Clinical Trials Browser

Phase 1/2 × OTHER × GBM × Clear all

NCT05973903 2024-12-04

Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma

Phase 1/2 Withdrawn

GBM